Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Paclitaxel for Malignant Peritoneal Mesothelioma
NCT05449366Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Feb 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel in malignant peritoneal mesothelioma (MPM), sponsored by Erasmus MC. Started Feb 2022; status: completed.
02
Drugs
paclitaxel
03
Conditions
malignant peritoneal mesothelioma (MPM)
Beyond the preview
Go deeper on NCT05449366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05449366.